PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
222 hedge funds and large institutions have $1.41B invested in PDL BioPharma, Inc. in 2014 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 96 increasing their positions, 68 reducing their positions, and 35 closing their positions.
105% more call options, than puts
Call options by funds: $4.12M | Put options by funds: $2.02M
41% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 68
20% more capital invested
Capital invested by funds: $1.18B → $1.41B (+$234M)
5% less funds holding
Funds holding: 233 → 222 (-11)
29% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$21M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$12.6M |
| 3 |
AAM
Advisors Asset Management
Monument,
Colorado
|
+$9.38M |
| 4 |
Renaissance Technologies
New York
|
+$9.25M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$9.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$11.9M |
| 2 |
HSA
Hussman Strategic Advisors
Ellicott City,
Maryland
|
-$9.03M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$7.84M |
| 4 |
GAM
Gotham Asset Management
New York
|
-$7.81M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$6.1M |
PDLI Hedge Fund Activity: Q2 2014 in Review
222 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q2 2014, worth a combined $1.41B — up 20% from $1.18B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of PDLI and 25 opened new positions — a net loss of 10 holders — while 68 trimmed existing stakes and 96 added.
The largest buyer was Norges Bank, adding an estimated $21M. The largest seller was Two Sigma Investments, cutting an estimated $11.9M.
- 222 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q2 2014, down from 233 in Q1 2014.
- Funds reported $1.41B of PDL BioPharma, Inc. stock for Q2 2014, up 20% quarter-over-quarter.
- 25 funds opened new PDL BioPharma, Inc. positions in Q2 2014 and 35 closed out, a net change of -10 holders.
- The largest PDL BioPharma, Inc. buyer in Q2 2014 was Norges Bank, an estimated $21M added.
- The largest PDL BioPharma, Inc. seller in Q2 2014 was Two Sigma Investments, an estimated $11.9M sold.
Based on aggregated 13F filings for Q2 2014.